133 related articles for article (PubMed ID: 33208672)
1. PAX8 Expression in Breast Cancer.
Lu S; Yakirevich E; Hart J; Wang L; Wang Y
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):293-298. PubMed ID: 33208672
[TBL] [Abstract][Full Text] [Related]
2. Comparison of PAX8 Expression in Breast Carcinoma Using MRQ50 and BC12 Monoclonal Antibodies.
Singh K; Hanley LC; Sung CJ; Quddus MR
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):558-561. PubMed ID: 31335489
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
4. Unexpected PAX8 Immunoreactivity in Metastatic High-grade Breast Cancer.
Kilgore MR; Bosch DE; Adamson KH; Swanson PE; Dintzis SM; Rendi MH
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):637-643. PubMed ID: 30358609
[TBL] [Abstract][Full Text] [Related]
5. Polyclonal PAX8 expression in carcinomas of the biliary tract - Frequent non-specific staining represents a potential diagnostic pitfall.
Zong Y; Xiong Y; Dresser K; Yang M; Bledsoe JR
Ann Diagn Pathol; 2021 Aug; 53():151762. PubMed ID: 34102541
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Paired Box 8 (PAX8)-expressing Metastatic Breast Carcinoma.
Kim SW; Kim HS; Na K
Anticancer Res; 2020 Oct; 40(10):5925-5932. PubMed ID: 32988924
[TBL] [Abstract][Full Text] [Related]
7. PAX-8 Expression in Salivary Duct Carcinoma.
Serinelli S; Mirchia K; Gitto L; Khurana KK; Zaccarini DJ
Appl Immunohistochem Mol Morphol; 2021 Oct; 29(9):680-684. PubMed ID: 34081633
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Utility of Pax8, Pax2, and NGFR Immunohistochemical Expression in Pediatric Renal Tumors.
Arva NC; Bonadio J; Perlman EJ; Cajaiba MM
Appl Immunohistochem Mol Morphol; 2018; 26(10):721-726. PubMed ID: 28426529
[TBL] [Abstract][Full Text] [Related]
9. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison.
Ozcan A; Liles N; Coffey D; Shen SS; Truong LD
Am J Surg Pathol; 2011 Dec; 35(12):1837-47. PubMed ID: 21989345
[TBL] [Abstract][Full Text] [Related]
10. Unusual staining of immunohistochemical markers PAX8 and CDX2 in breast carcinoma: a potential diagnostic pitfall.
Shen T; Zhao J; Zhao M; Taggart MW; Ramalingam P; Gong Y; Wu Y; Liu H; Zhang J; Resetkova E; Wang WL; Ding Q; Huo L; Yoon E
Hum Pathol; 2022 Jul; 125():35-47. PubMed ID: 35417734
[TBL] [Abstract][Full Text] [Related]
11. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.
Woodard AH; Yu J; Dabbs DJ; Beriwal S; Florea AV; Elishaev E; Davison JM; Krasinskas AM; Bhargava R
Am J Clin Pathol; 2011 Sep; 136(3):428-35. PubMed ID: 21846919
[TBL] [Abstract][Full Text] [Related]
12. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
Nonaka D; Chiriboga L; Soslow RA
Am J Surg Pathol; 2008 Oct; 32(10):1566-71. PubMed ID: 18724243
[TBL] [Abstract][Full Text] [Related]
13. Malignant tumors with clear cell morphology: a comparative immunohistochemical study with renal cell carcinoma antibody, Pax8, steroidogenic factor 1, and brachyury.
Clayton EF; Ziober A; Yao Y; Bing Z
Ann Diagn Pathol; 2013 Apr; 17(2):192-7. PubMed ID: 23218904
[TBL] [Abstract][Full Text] [Related]
14. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1.
Weissferdt A; Tang X; Wistuba II; Moran CA
Mod Pathol; 2013 Dec; 26(12):1554-60. PubMed ID: 23787439
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
[TBL] [Abstract][Full Text] [Related]
16. CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors.
Chiesa-Vottero A
Int J Gynecol Pathol; 2020 Mar; 39(2):170-177. PubMed ID: 32045390
[TBL] [Abstract][Full Text] [Related]
17. High-Grade Endometrioid Carcinoma of the Endometrium With a GATA-3-Positive/PAX8-Negative Immunophenotype Metastatic to the Breast: A Potential Diagnostic Pitfall.
Salibay C; Fadare O
Int J Surg Pathol; 2020 Sep; 28(6):631-636. PubMed ID: 32188328
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of PAX8 Expression in Epithelial Malignancies of the Uterine Cervix.
Wong S; Hong W; Hui P; Buza N
Int J Gynecol Pathol; 2017 Mar; 36(2):101-106. PubMed ID: 27362905
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of PAX8, PAX2, and cytokeratin in melanomas.
Plotzke JM; Zhao R; Hrycaj SM; Harms PW; Mehra R; Chan MP
J Cutan Pathol; 2021 Oct; 48(10):1246-1251. PubMed ID: 33934372
[TBL] [Abstract][Full Text] [Related]
20. PAX8-positive Biphasic Synovial Sarcoma Expressing Hormonal Receptors.
Lordello L; Bur ME; Oliva E; Lennerz JK
Appl Immunohistochem Mol Morphol; 2019 Aug; 27(7):e71-e74. PubMed ID: 28248726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
